Literature DB >> 17619877

11C/ 18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?

Cristina Nanni, Paolo Castellucci, Mohsen Farsad, Domenico Rubello, Stefano Fanti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17619877     DOI： 10.1007/s00259-007-0491-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  18 in total

1.  Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy.

Authors:  Alberto Briganti; Felix K-H Chun; Andrea Salonia; Giuseppe Zanni; Vincenzo Scattoni; Luc Valiquette; Patrizio Rigatti; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2006-02-17       Impact factor: 20.096

2.  Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001.

Authors:  Aruna V Sarma; David Schottenfeld
Journal:  Semin Urol Oncol       Date:  2002-02

3.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

Authors:  M Picchio; C Messa; C Landoni; L Gianolli; S Sironi; M Brioschi; M Matarrese; D V Matei; F De Cobelli; A Del Maschio; F Rocco; P Rigatti; F Fazio
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

4.  Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

Authors:  Igle J de Jong; Jan Pruim; Philip H Elsinga; Willem Vaalburg; Han J Mensink
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

5.  In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.

Authors:  Anthonius J Breeuwsma; Jan Pruim; Maud M Jongen; Albert J Suurmeijer; Wim Vaalburg; Rien J Nijman; Igle J de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-12       Impact factor: 9.236

6.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells.

Authors:  M Yoshimoto; A Waki; Y Yonekura; N Sadato; T Murata; N Omata; N Takahashi; M J Welch; Y Fujibayashi
Journal:  Nucl Med Biol       Date:  2001-02       Impact factor: 2.408

7.  PET imaging of prostate cancer using carbon-11-choline.

Authors:  T Hara; N Kosaka; H Kishi
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

8.  11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

9.  Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas.

Authors:  Toshihiko Hara; Tatsuya Kondo; Tetsuo Hara; Noboru Kosaka
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

10.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057
View more
  7 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

Review 3.  Positron emission tomography imaging of prostate cancer.

Authors:  Hao Hong; Yin Zhang; Jiangtao Sun; Weibo Cai
Journal:  Amino Acids       Date:  2009-11-28       Impact factor: 3.520

4.  [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology.

Authors:  Orjan Lindhe; Aijun Sun; Johan Ulin; Obaidur Rahman; Bengt Långström; Jens Sörensen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-22       Impact factor: 9.236

Review 5.  18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.

Authors:  Claudia Brogsitter; Klaus Zöphel; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

6.  Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.

Authors:  Rogier P J Schroeder; W M van Weerden; E P Krenning; C H Bangma; S Berndsen; C H Grievink-de Ligt; H C Groen; S Reneman; E de Blois; W A P Breeman; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-23       Impact factor: 9.236

7.  Imaging with non-FDG PET tracers: outlook for current clinical applications.

Authors:  Egesta Lopci; Cristina Nanni; Paolo Castellucci; Gian Carlo Montini; Vincenzo Allegri; Domenico Rubello; Franca Chierichetti; Valentina Ambrosini; Stefano Fanti
Journal:  Insights Imaging       Date:  2010-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.